AAAAAA

   
Results: 1-10 |
Results: 10
BLACK-BOX WARNINGS IN PRESCRIPTION DRUG LABELING - RESULTS OF A SURVEY OF 206 DRUGS
Authors: BEACH JE FAICH GA BORMEL FG SASINOWSKI FJ
Citation: Je. Beach et al., BLACK-BOX WARNINGS IN PRESCRIPTION DRUG LABELING - RESULTS OF A SURVEY OF 206 DRUGS, Food and drug law journal, 53(3), 1998, pp. 403-411
EFFECT OF ONYCHOMYCOSIS ON QUALITY-OF-LIFE
Authors: DRAKE LA SCHER RK SMITH EB FAICH GA SMITH SL HONG JJ STILLER MJ
Citation: La. Drake et al., EFFECT OF ONYCHOMYCOSIS ON QUALITY-OF-LIFE, Journal of the American Academy of Dermatology, 38(5), 1998, pp. 702-704
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE - SAFER THAN IRON DEXTRAN
Authors: FAICH GA STROBOS J
Citation: Ga. Faich et J. Strobos, SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE - SAFER THAN IRON DEXTRAN, Journal of the American Society of Nephrology, 8, 1997, pp. 894-894
DRUG TO TREAT OBESITY - EDITORIAL WRITER RESPONDS
Authors: FAICH GA
Citation: Ga. Faich, DRUG TO TREAT OBESITY - EDITORIAL WRITER RESPONDS, CMAJ. Canadian Medical Association journal, 156(7), 1997, pp. 978-978
PHARMACOTHERAPY FOR OBESITY - DO THE BENEFITS OUTWEIGH THE RISKS
Authors: MANSON JE FAICH GA
Citation: Je. Manson et Ga. Faich, PHARMACOTHERAPY FOR OBESITY - DO THE BENEFITS OUTWEIGH THE RISKS, The New England journal of medicine, 335(9), 1996, pp. 659-660
CONFLICTS-OF-INTEREST - EDITORIALISTS RESPOND
Authors: MANSON JE FAICH GA
Citation: Je. Manson et Ga. Faich, CONFLICTS-OF-INTEREST - EDITORIALISTS RESPOND, The New England journal of medicine, 335(14), 1996, pp. 1064-1065
A MULTICENTER STUDY ASSESSING THE EFFECT OF ONYCHOMYCOSIS ON QUALITY-OF-LIFE INCLUDING FUNCTIONAL, PSYCHOSOCIAL AND ECONOMIC-ASPECTS
Authors: SMITH SL DRAKE LA SCHER RK SMITH EB FAICH GA HONG JJ STILLER MJ
Citation: Sl. Smith et al., A MULTICENTER STUDY ASSESSING THE EFFECT OF ONYCHOMYCOSIS ON QUALITY-OF-LIFE INCLUDING FUNCTIONAL, PSYCHOSOCIAL AND ECONOMIC-ASPECTS, Journal of investigative dermatology, 106(4), 1996, pp. 517-517
FDA AND DRUG APPROVAL
Authors: FAICH GA
Citation: Ga. Faich, FDA AND DRUG APPROVAL, Journal of vascular and interventional radiology, 6(6), 1995, pp. 24-24
POSTMARKETING SURVEILLANCE - BEYOND MEDWATCH
Authors: FAICH GA
Citation: Ga. Faich, POSTMARKETING SURVEILLANCE - BEYOND MEDWATCH, JAMA, the journal of the American Medical Association, 270(18), 1993, pp. 2180-2180
CLUSTERING OF ADVERSE DRUG EVENTS - ANALYSIS OF RISK-FACTORS FOR CEREBELLAR TOXICITY WITH HIGH-DOSE CYTARABINE
Authors: JOLSON HM BOSCO L BUFTON MG GERSTMAN BB RINSLER SS WILLIAMS E FLYNN B SIMMONS WD STADEL BV FAICH GA PECK C
Citation: Hm. Jolson et al., CLUSTERING OF ADVERSE DRUG EVENTS - ANALYSIS OF RISK-FACTORS FOR CEREBELLAR TOXICITY WITH HIGH-DOSE CYTARABINE, Journal of the National Cancer Institute, 84(7), 1992, pp. 500-505
Risultati: 1-10 |